Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: An exploratory analysis

Journal of Proteomics

Volumn 77, Issue , 2012, Pages 372-382

  Ortea, Ignacio ^a   Roschitzki, Bernd ^b   Ovalles, Juan Gabriel ^c   Longo, Javier López ^c   de la Torre, Inmaculada ^c   González, Isidoro ^d   Gómez Reino, Juan J ^a,e   González, Antonio ^a  

^a Santiago University Clinical Hospital   (Spain)

^b ETH ZURICH   (Switzerland)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Infliximab; Response prediction; Rheumatoid arthritis; Serum biomarkers

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A2; APOLIPOPROTEIN B100; APOLIPOPROTEIN M; CERULOPLASMIN; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4B; COMPLEMENT FACTOR H; FIBRONECTIN; GELSOLIN; INFLIXIMAB; INTER ALPHA TRYPSIN INHIBITOR; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; THROMBOSPONDIN 1; VITAMIN D BINDING PROTEIN;

ACUTE PHASE RESPONSE; ADIPOCYTE MEMBRANE; ARTICLE; COMPLEMENT SYSTEM; HUMAN; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD PROTEINS; FEMALE; HUMANS; MALE; PROTEOME; PROTEOMICS;

EID: 84870391101     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.09.011     Document Type: Article

References (80)

1. Scott D.L., Wolfe F., Huizinga T.W. Rheumatoid arthritis. Lancet 2010, 376:1094-1108.
2. Rutgeers P., Van Assche G., Vermiere S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004, 126:1593-1610.
3. Isaacs J.D., Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis 2011, 70:4-7.
4. Emery P., Dörner T. Optimising treatment in rheumatoid arthritis: a review of potencial biological markers of response. Ann Rheum Dis 2011, 70:2063-2070.
5. Fabre S., Dupuy A.M., Dossat N., Guisset C., Cohen J.D., Cristol J.P., et al. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol 2008, 153:188-195.
6. Hueber W., Tomooka B.H., Batliwalla F., Li W., Monach P.A., Tibshirani R.J., et al. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Res Ther 2009, 11:R76.
7. Fabre S., Guisset C., Tatem L., Dossat N., Dupuy A.M., Cohen J.D., et al. Protein biochip array technology to monitor rituximab in rheumatoid arthritis. Clin Exp Immunol 2009, 155:395-402.
8. Trocmé C., Marotte H., Baillet A., Ballot-Prades B., Garin J., Grange L., et al. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1328-1333.
9. Liao H., Wu J., Kuhn E., Chin W., Chang B., Jones M.D., et al. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum 2004, 50:3792-3803.
10. Uchida T., Fukawa A., Uchida M., Fujita K., Saito K. Application of a novel protein biochip technology for detection and identification or rheumatoid arthritis biomarkers in synovial fluid. J Proteome Res 2002, 1:495-499.
11. De Seny D., Fillet M., Meuwis M.A., Geurts P., Lutteri L., Ribbens C., et al. Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach. Arthritis Rheum 2005, 52:3801-3812.
12. Jin E.H., Shim S.C., Kim H.G., Chae S.C., Chung H.T. Polymorphisms of COTL1 gene identified by proteomic approach and their association with autoimmune disorders. Exp Mol Med 2009, 41:354-361.
13. Zheng X., Wu S.L., Hincapie M., Hancock W.S. Study of the human plasma proteome of rheumatoid arthritis. J Chromatogr A 2009, 1216:3538-3545.
14. Goëb V., Thomas-L'Otellier M., Daveau R., Charlionet R., Fardellone P., Le Loët X., et al. Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes. Arthritis Res Ther 2009, 11:R38.
15. Li T.W., Zheng B.R., Huang Z.X., Lin Q., Zhao L.K., Liao Z.T., et al. Screening disease-associated proteins from sera of patients with rheumatoid arthritis: a comparative proteomic study. Chin Med J (Engl) 2010, 123:537-543.
16. Serada S., Fujimoto M., Ogata A., Terabe F., Hirano T., Iijima H., et al. iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases. Ann Rheum Dis 2010, 69:770-774.
17. Van Steendam K., Tilleman K., De Ceuleneer M., De Keyser F., Elewaut D., Deforce D. Citrullinated vimentin as an important antigen in immune complexes from synovial fluid of rheumatoid arthritis patients with antibodies against citrullinated proteins. Arthritis Res Ther 2010, 12:R132.
18. Long L., Li R., Li Y., Hu C., Li Z. Pattern-based diagnosis and screening of differentially expressed serum proteins for rheumatoid arthritis by proteomic fingerprinting. Rheumatol Int 2011, 31:1069-1074.
19. Zhang X., Yuan Z., Shen B., Zhu M., Liu C., Xu W. Discovery of serum protein biomarkers in rheumatoid arthritis using MALDI-TOF-MS combined with magnetic beads. Clin Exp Med 2012, 12:145-151.
20. Mateos J., Lourido L., Fernández-Puente P., Calamia V., Fernández-López C., Oreiro N., et al. Differential protein profiling of synovial fluid from rheumatoid arthritis and osteoarthritis patients using LC-MALDI-TOF/TOF. J Proteomics 2012, 75:2869-2878.
21. Sekigawa I., Yanagida M., Iwabuchi K., Kaneda K., Kaneko H., Takasaki Y., et al. Protein biomarker analysis by mass spectrometry in patients with rheumatoid arthritis receiving anti-tumor necrosis factor-alpha antibody therapy. Clin Exp Rheumatol 2008, 26:261-267.
22. Dwivedi R.C., Dhindsa N., Krokhin O.V., Cortens J., Wilkins J.A., El-Gabalawy H.S. The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients. Arthritis Res Ther 2009, 11:R32.
23. Surinova S., Schiess R., Hüttenhain R., Cerciello F., Wollscheid B., Aeberdold R. On the development of plasma protein biomarkers. J Proteome Res 2011, 10:5-16.
24. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
25. Van Gestel A.M., Haaqsma C.J., van Riel P.L. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998, 41:1845-1850.
26. Shilov I.V., Seymour S.L., Patel A.A., Loboda A., Tang W.H., Keating S.P., et al. The Paragon Algorithm: a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol Cell Proteomics 2007, 6:1638-1655.
27. Elias J.E., Gygi S.P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods 2007, 4:207-214.
28. Linden A. Measuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristic (ROC) analysis. J Eval Clin Pract 2006, 12:132-139.
29. Wader K.F., Fagerli U.M., Holt R.U., Stordal B., Borset M., Sundan A., et al. Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma. Eur J Haematol 2008, 81:380-383.
30. Cunningham S.K., Loughlin T., Culliton M., McKenna T.J. Plasma sex hormone-binding globulin levels decrease during the second decade of life irrespective of pubertal status. J Clin Endocrinol Metab 1984, 58:915-918.
31. Mash D.C., Adi N., Duque L., Pablo J., Kumar M., Ervin F.R. Alpha synuclein protein levels are increased in serum from recently abstinent cocaine abusers. Drug Alcohol Depend 2008, 94:246-250.
32. Tönjes A., Fasshauer M., Kratzsch J., Stumvoll M., Blüher M. Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS One 2010, 5:e13911.
33. Ernoult E., Gamelin E., Guette C. Improved proteome coverage by using iTRAQ labelling and peptide OFFGEL fractionation. Proteome Sci 2008, 6:27.
34. Lößner C., Blackstock W., Gunaratne J. Enhanced performance of pulsed Q collision induced dissociation-based peptide identification on a dual-pressure linear ion trap. J Am Soc Mass Spectrom 2012, 23:186-189.
35. Pichler P., Köcher T., Holzmann J., Mazanek M., Taus T., Ammerer G., et al. Peptide labeling with isobaric tags yields higher identification rates using iTRAQ 4-plex compared with TMT 6-plex and iTRAQ 8-plex on LTQ Orbitrap. Anal Chem 2010, 82:6549-6558.
36. Guo T., Gan C.S., Zhang H., Zhu Y., Kon O.L., Sze S.K. Hybridization of pulsed-Q dissociation and collision-activated dissociation in linear ion trap mass spectrometer for iTRAQ quantitation. J Proteome Res 2008, 7:4831-4840.
37. Zhang Y., Ficarro S.B., Li S., Marto J.A. Optimized orbitrap HCD for quantitative analysis of phosphopeptides. J Am Soc Mass Spectrom 2009, 20:1425-1434.
38. Köcher T., Pichler P., Schutzbier M., Stingl C., Kaul A., Teucher N., et al. High precision quantitative proteomics using iTRAQ on a LTQ Orbitrap: a new mass spectrometric method combining the benefits of all. J Proteome Res 2009, 8:4743-4752.
39. Noirel J., Evans C., Salim M., Mukherjee J., Ow S.Y., Pandhal J., et al. Methods in quantitative proteomics: setting iTRAQ on the right track. Curr Proteomics 2011, 8:17-30.
40. Wessels J.A., van der Kooij S.M., le Cessie S., Kievit W., Barerra P., Allaart C.F., et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 2007, 56:1765-1775.
41. Raterman H.G., Vosslamber S., de Ridder S., Nurmohamed M.T., Lems W.F., Boers M., et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 2012, 14:R95.
42. Aletaha D., Funovits J., Keystone E.C., Smolen J.S. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007, 56:3226-3235.
43. van der Helm-van Mil A.H., Toes R.E., Huizinga T.W. Genetic variants in the prediction of rheumatoid arthritis. Ann Rheum Dis 2010, 69:1694-1696.
44. van der Helm-van Mil A.H., le Cessie S., van Dongen H., Breedveld F.C., Toes R.E., Huizinga T.W. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007, 56:433-440.
45. van der Helm-van Mil A.H., Detert J., le Cessie S., Filer A., Bastian H., Burmester G.R., et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum 2008, 58:2241-2247.
46. Ow S.Y., Salim M., Noirel J., Evans C., Rehman I., Wright P.C. iTRAQ underestimation in simple and complex mixtures: the good, the bad and the ugly. J Proteome Res 2009, 8:5347-5355.
47. Sierra-Johnson J., Fisher R.M., Romero-Corral A., Somers V.K., Lopez-Jimenez F., Ohrvik J., et al. Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur Heart J 2009, 30:710-717.
48. Julve J., Escola-Gil J.C., Rotllan N., Fievet C., Vallez E., de la Torre C., et al. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome. Arterioscler Thromb Vasc Biol 2010, 30:232-238.
49. Elsøe S., Ahnström J., Christoffersen C., Hoofnagle A.N., Plomgaard P., Heinecke J.W., et al. Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL. Atherosclerosis 2012, 221:91-97.
50. Aviña-Zubieta J.A., Choi H.K., Sadatsafavi M., Etminan M., Esdaille J.M., Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008, 59:1690-1697.
51. Park Y.B., Lee S.K., Lee W.K., Suh C.H., Lee C.W., Lee C.H., et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999, 26:1701-1704.
52. Steiner G., Urowitz M.B. Lipid Profiles in Patients with Rheumatoid Arthritis: Mechanisms and the Impact of Treatment. Semin Arthritis Rheum 2009, 38:372-381.
53. Choy E., Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009, 68:460-469.
54. Park Y.B., Choi H.K., Kim M.Y., Lee W.K., Song J., Kim D.K., et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002, 113:188-193.
55. Daïen C.I., Duny Y., Barnetche T., Daurès J.P., Combe B., Morel J. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 2012, 71:862-868.
56. Hyka N., Dayer J.M., Modoux C., Kohno T., Edwards C.K., Roux-Lombard P., et al. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001, 97:2381-2389.
57. Ketelhuth D.F., Rios F.J., Wang Y., Liu H., Johansson M.E., Fredrikson G.N., et al. Identification of a danger-associated peptide from apolipoprotein B100 (ApoBDS-1) that triggers innate proatherogenic responses. Circulation 2011, 124:2433-2443.
58. Gomaraschi M., Sinagra G., Serdoz L.V., Pitzorno C., Fonda M., Cattin L., et al. The plasma concentration of Lpa-I:A-II particles as a predictor of the inflammatory response in patients with ST-elevation myocardial infarction. Atherosclerosis 2009, 202:304-311.
59. Schippers E.F., Berbée J.F.P., Van Disseldorp I.M., Versteegh M.I.M., Havekes L.M., Rensen P.C.N., et al. Preoperative apolipoprotein CI levels correlate positively with the proinflammatory response in patients experiencing endotoxemia following elective cardiac surgery. Intensive Care Med 2008, 34:1492-1497.
60. Watanabe J., Charles-Schoeman C., Miao Y., Elashoff D., Yin Lee Y., Katselis G., et al. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum 2012, 64:1828-1837.
61. Van Lenten B.J., Hama S.Y., de Beer F.C., Stafforini D.M., McIntyre T.M., Prescott S.M., et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995, 96:2758-2767.
62. Bogner-Strauss J.G., Prokesch A., Sanchez-Cabo F., Rieder D., Hackl H., Duszka K., et al. Reconstruction of gene association network reveals a transmembrane protein required for adipogenesis and targeted by PPARγ. Cell Mol Life Sci 2010, 67:4049-4064.
63. Hebecker M., Józsi M. Factor H-related protein 4 activates complement by serving as a platform for the assembly of an alternative pathway C3 convertase via its interaction with C3b protein. J Biol Chem 2012, 287:19528-19536.
64. Fritsche L.G., Lauer N., Hartmann A., Stippa S., Keilhauer C.N., Oppermann M., et al. An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum Mol Genet 2010, 19:4694-4704.
65. Thiel S., Vorup-Jensen T., Stover C.M., Schwaeble W., Laursen S.B., Poulsen K., et al. A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997, 386:506-510.
66. Okroj M., Holmquist E., Sjölander J., Corrales L., Saxne T., Wisniewski H.G., et al. Heavy chains of inter alpha inhibitor (IαI) inhibit the human complement system at early stages of the cascade. J Biol Chem 2012, 287:20100-20110.
67. Solomon S., Kassahn D., Illges H. The role of the complement and the FcγR system in the pathogenesis of arthritis. Arthritis Res Ther 2005, 7:129-135.
68. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448-454.
69. Banha J., Marques L., Oliveira R., Martins M.F., Paixao E., Pereira D., et al. Ceruloplasmin expression by human peripheral blood lymphocytes: a new link between immunity and iron metabolism. Free Radic Biol Med 2008, 44:483-492.
70. Lopez-Dee Z., Pidcock K., Gutierrez L.S. Thrombospondin-1: multiple paths to inflammation. Mediators Inflamm 2011, 2011:296069.
71. Speeckaert M.M., Wehlou C., Vandewalle S., Taes Y.E., Robberecht E., Delangue J.R. Vitamin D binding protein, a new nutritional marker in cystic fibrosis patients. Clin Chem Lab Med 2008, 46:365-370.
72. Yamamoto N., Homma S. Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci U S A 1991, 88:8539-8543.
73. Clemmensen I., Holund B., Andersen R.B. Fibrin and fibronectin in rheumatoid synovial membrane and rheumatoid synovial fluid. Arthritis Rheum 1983, 26:479-485.
74. van Beers J.J., Willemze A., Stammen-Vogelzangs J., Drijfhout J.W., Toes R.E., Pruijn G.J.M. Anti-citrullinated fibronectin antibodies in rheumatoid arthritis are associated with human leukocyte antigen-DRB1 shared epitope alleles. Arthritis Res Ther 2012, 14:R35.
75. van Venrooij W.J., Pruijn G.J.M. An important step towards completing the rheumatoid arthritis cycle. Arthritis Res Ther 2008, 10:117.
76. Rico M.C., Manns J.M., Driban J.B., Uknis A.B., Kunapuli S.P., dela Cadena R.A. Thrombospondin-1 and transforming growth factor beta are pro-inflammatory molecules in rheumatoid arthritis. Transl Res 2008, 152:95-98.
77. Emery P., Dörner T. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis 2011, 70:2063-2070.
78. Bucki R., Kulakowska A., Byfield F.J., Zendzian-Piotrowska M., Baranowski M., Marzec M., et al. Plasma gelsolin modulates cellular response to sphingosine 1-phosphate. Am J Physiol Cell Physiol 2010, 299:C1516-C1523.
79. Osborn T.M., Verdrengh M., Stossel T.P., Tarkowski A., Bokarewa M. Decreased levels of the gelsolin plasma isoform in patients with rheumatoid arthritis. Arthritis Res Ther 2008, 10:R117.
80. Meuwis M.A., Fillet M., Lutteri L., Marée R., Geurts P., de Seny D., et al. Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study. Clin Biochem 2008, 41:960-967.